This is an outdated version published on 2023-07-13. Read the most recent version.

Smoking treatment guided by genetic markers


Authors

  • Gloria Hincapié López Español
  • Carlos Alberto Isaza Mejía Centro de Células Madre y Biotecnología (Cemab)
  • Robert Santafé Sánchez Universidad de Manizales https://orcid.org/0000-0002-1871-0516
  • Leonardo Beltrán Angarita Universidad Tecnológica de Pereira

DOI:

https://doi.org/10.22517/25395203.25205

Keywords:

Bupropion, CYP2A6, CYP2B6, nicotina, reporte de casos, tabaquismo

Abstract

Introduction: Among drug addictions, smoking ranks first as a cause of morbidity and mortality and is a risk factor for six of the eight leading causes of death in the world. Nicotine is the main addictive component of tobacco. In nicotine replacement therapy (NRT), varenicline and bupropion are the approved medications for smoking cessation, but results from smoking cessation clinics suggest that many variables influencing treatment response remain unknow.

Objective: To determine the adherence, tolerability and effectiveness of a smoking cessation program based on nicotine or bupropion, in patients with tobacco dependence, selected according to the genotypes of the enzymes that metabolize the two drugs.

Clinical findings: Twenty-one smokers, 67% men, with mean age of 46.2±11.7 years, were included in this series. Their smoking began at 17.8±6 years and they had been smoking for 28±13 years.

At baseline, they smoked 17±12 cigarettes per day (CPD), had made 3.7±2 quit attempts, the NDSS (Nicotine Dependence Short Scale Screening Scale) score was 22±5 (cut-off point for nicotine dependence: 11 or more points).

Treatment: Patients had free telephone access to the treating physician and, every week, a consultation consisting of counseling and monitoring of the prescribed pharmacological treatment according to CYP2A6 (encoding the enzyme that metabolizes nicotine) and CYP2B6 (encoding the enzyme that metabolizes bupropion) genotypes. Nicotine was used in 14 mg transdermal patches for the first month and then 7 mg for the second month, supplemented with chewing gum for withdrawal management and bupropion in a 300 mg controlled-release form, 1-2 times a day.

Results: After 8 weeks of treatment and 4 weeks of observation, 15 subjects (71.4%) responded partially/totally. CPD consumption dropped from 17±12 at the beginning of the study to 2.2±3.5 at the end of the study, which corresponds to a reduction of 195 cigarettes/day. Seven of eight patients treated with bupropion (87.5%) and seven of thirteen treated with nicotine (54%) had a partial/total response. Only one patient receiving nicotine discontinued the medication due to gastrointestinal intolerance (nausea and vomiting). The relapse rate, assessed one month after drug treatment, was zero. Good genotype-phenotype correlation was found in individuals treated with bupropion, but not in those treated with nicotine.

Clinical relevance: The inclusion of pharmacogenetic markers for the choice of nicotine or bupropion in a smoking cessation program may improve adherence, drug tolerability, and treatment effectiveness.

Downloads

Download data is not yet available.

Author Biographies

Gloria Hincapié López, Español

Docente, Universidad Tecnológica de Pereira

Médica

Especialista en Bioquímica Clínica

PhD Ciencias Biomédicas

Carlos Alberto Isaza Mejía, Centro de Células Madre y Biotecnología (Cemab)

Director científico, Centro de Células Madre y Biotecnología (Cemab)

Médico

Especialista en Farmacología Clínica

Robert Santafé Sánchez, Universidad de Manizales

Médico

Especialista en Medicina Crítica y Cuidados Intensivos

PhD(c) en Ciencias Biomédicas

Leonardo Beltrán Angarita , Universidad Tecnológica de Pereira

Docente

Químico Farmacéutico

References

Organización Mundial de la Salud. Tabaco. [internet] 20232[consultado 11/02/2022] Dis- poninle en: https://www.who.int/es/news-room/fact-sheets/detail/tobacco.

República de Colombia. Ministerio de Salud y Protección Social. Programa para la cesación del consumo de tabaco y atención del tabaquismo. 2017.

Johnson AL, Nystrom NC, Piper ME, Cook J, Norton DL, Zuelsdorff M, et al. Cigarette Smoking Status, Cigarette Exposure, and Duration of Abstinence Predicting Incident De- mentia and Death: A Multistate Model Approach. J Alzheimers Dis. 2021. doi: 10.3233/ JAD-201332.

Verdejo-Garcia A, Albein-Urios N. Impulsivity traits and neurocognitive mechanisms con- ferring vulnerability to substance use disorders. Neuropharmacology. 2020;183:108402. doi: 10.1016/j.neuropharm.2020.108402.

Kumar N, Janmohamed K, Jiang J, Ainooson J, Billings A, Chen GQ, et al. Tobacco cessa- tion in low- to middle-income countries: A scoping review of randomized controlled trials. Addict Behav. 2021;112:106612. doi: 10.1016/j.addbeh.2020.106612.

Patnode CD, Henderson JT, Coppola EL, Melnikow J, Durbin S, Thomas RG. Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325(3):280- 298. doi: 10.1001/jama.2020.23541.

Xu K, Li B, McGinnis KA, Vickers-Smith R, Dao C, Sun N, et al. Genome-wide association study of smoking trajectory and meta-analysis of smoking status in 842,000 individuals. Nat Commun. 2020;11(1):5302. doi: 10.1038/s41467-020-18489-3.

Salloum NC, Buchalter ELF, Chanani S, Espejo G, Ismail MS, Laine RO, et al. From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. Pharmaco- genomics. 2018;19(10):861-871. doi: 10.2217/pgs-2018-0023.

Tran AX, Ho TT, Varghese Gupta S. Role of CYP2B6 pharmacogenomics in bupropion- mediated smoking cessation. J Clin Pharm Ther. 2019;44(2):174-179. doi: 10.1111/ jcpt.12783.

Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, Saccone N, Hatsukami D, Goate A, Bierut L. Pharmacotherapy effects on smoking cessation vary with nicotine meta- bolism gene (CYP2A6). Addiction. 2014;109(1):128-37. doi:10.1111/add.12353.

Asfar T, Arheart KL, McClure LA, Ruano-Herreria EC, Dietz NA, Ward KD, et al. Im- plementing a Novel Workplace Smoking Cessation Intervention Targeting Hispanic/ Latino Construction Workers: A Pilot Cluster Randomized Trial. Health Educ Behav. 2020:1090198120960395. doi: 10.1177/1090198120960395.

Muderrisoglu A, Babaoglu E, Korkmaz ET, Ongun MC, Karabulut E, Iskit AB, et al. Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation. Front Genet. 2020;11:571997. doi: 10.3389/fgene.2020.571997.

Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, Lindson N. Antidepres- sants for smoking cessation. Cochrane Database Syst Rev. 2020;4(4):CD000031. doi: 10.1002/14651858.CD000031.pub5.

Chenoweth MJ, Tyndale RF. Pharmacogenetic Optimization of Smoking Cessation Treatment. Trends Pharmacol Sci. 2017;38(1):55-66. doi: 10.1016/j.tips.2016.09.006.

Tanner JA, Tyndale RF. Variation in CYP2A6 Activity and Personalized Medicine. J Pers Med. 2017;7(4):18. doi: 10.3390/jpm7040018.

REVISTA MÉDICA RISARALDA 2023

⏐117

REVISTA MÉDICA RISARALDA 2023

Fang Y, Wang T, Guo YY, Zhang HF, Wen Q, Xing YR, et al. From Genotype to Phenotype: Content and Activities of Cytochromes P450 2A6 in Human Liver In Vitro and Predicted In Vivo. J Pharmacol Exp Ther. 2020;372(3):320-330. doi: 10.1124/jpet.119.263152.

Zhu AZ., Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, et al. CYP2B6 and bupropion’s smoking-cessation pharmacology: the roleof hydroxybupropion.Clin. Phar- macol. Ther. 2012; 92: 771–777. doi: 10.1038/clpt.2012.186..

Downloads

Published

2023-06-29 — Updated on 2023-07-13

Versions

How to Cite

Hincapié López, G., Isaza Mejía, C. A. ., Santafé Sánchez, R. ., & Beltrán Angarita , L. . (2023). Smoking treatment guided by genetic markers. Revista Médica De Risaralda, 29(1). https://doi.org/10.22517/25395203.25205 (Original work published June 29, 2023)